Clinical trial
A Double-blind, Randomised Study to Assess the Influence of Tiotropium…
NCT00257452 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00257452 |
|---|---|
| Title | A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®) |
| Official title | A Double-blind, Randomised, Placebo Controlled, Three-way Cross-over Study With an Open Label Positive Control (Moxifloxacin) to Assess the Influence of Inhaled Tiotropium Once Daily Over Twelve Days on the QTC Interval of the ECG in Healthy Male and Female Volunteers |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | tiotropium 18 mcg or 54 mcg qd, placebo matching tiotropium qd, moxifloxacin 200 mg |
| Enrollment | 56 |
| Start date | Oct 1, 2004 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Nov 23, 2005 |
| Last update posted | Nov 1, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: